financetom
Business
financetom
/
Business
/
Kingswood Capital Management Enters into a Definitive Agreement to Acquire Drive DeVilbiss Healthcare, a Leading Global Manufacturer and Supplier of Essential Medical Products
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kingswood Capital Management Enters into a Definitive Agreement to Acquire Drive DeVilbiss Healthcare, a Leading Global Manufacturer and Supplier of Essential Medical Products
Oct 16, 2025 5:13 AM

LOS ANGELES--(BUSINESS WIRE)--

Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) is pleased to announce it has signed a definitive agreement to acquire Drive DeVilbiss Healthcare (“Drive” or the “Company”) from CD&R. Drive’s existing management team will continue to lead the Company, ensuring continuity in customer relationships and strategic execution. Kingswood will leverage its extensive network, industry expertise, and capital base to support Drive’s continued growth. The transaction is expected to close later this year, subject to customary legal and regulatory requirements.

Founded in 2000, Drive is a leading global manufacturer and supplier of essential medical products used primarily in the home setting. Following the 2015 acquisition of DeVilbiss Healthcare, an innovator in respiratory care since 1888, the Company expanded from wheelchairs, beds, rollators and other homecare products to include a full line of reliable respiratory products used in more than 100 countries. Drive is committed to providing customers with the best possible products, ensuring excellent service, and serving as a dependable and consultative partner in the process. The Company is looking forward to continuing its mission to deliver innovative healthcare solutions that enhance the quality of life of the people it touches.

Derek Lampert, CEO of Drive, commented, “We are incredibly excited about our new partnership with Kingswood and are confident this new chapter for Drive DeVilbiss will be the most exciting yet. Kingswood is fully aligned with the management team on the company’s future growth strategy.”

Michael Niegsch, Partner at Kingswood, added, “We have been impressed with the company’s tremendous growth and success in recent years and we look forward to partnering with Derek and the rest of the Drive DeVilbiss management team to support the next phase of the company’s expansion.”

“Drive is well positioned for continued growth as a result of strong market tailwinds, organic growth initiatives, and actionable M&A opportunities,” said Alex Wolf, Founder and Managing Partner of Kingswood. “We’re looking forward to leveraging our deep operational network and expertise to support the company as it continues to grow and provide solutions to customers and patients around the world.”

J.P. Morgan is serving as exclusive financial advisor to Kingswood on the transaction and Kirkland & Ellis LLP is serving as legal counsel. UBS Investment Bank is serving as exclusive financial advisor to Drive and Debevoise & Plimpton LLP is serving as legal counsel to Drive and CD&R.

About Drive DeVilbiss Healthcare

Headquartered in Port Washington, New York, Drive DeVilbiss Healthcare manufactures and supplies a complete line of medical products, including mobility products, respiratory products, beds, pressure prevention products, self‐assist products, rehabilitation products, patient room equipment, personal care products and electrotherapy devices. Currently, the Company has offices, manufacturing facilities and distribution facilities located throughout the United States, Canada, the United Kingdom, France, Germany, China, Romania and Australia. The Company markets its products to customers located throughout the United States, Europe, United Kingdom, Canada, Mexico, Central and South America, Australia, the Middle East and Asia. For more information, visit www.drivemedical.com.

About Kingswood Capital Management, LP

Kingswood Capital Management, LP partners with leading companies in the middle market which stand to benefit from its capital and extensive operating resources. Kingswood embraces complexity and believes it is well-positioned to support businesses at inflection points in their development to enhance value. Based in Los Angeles, Kingswood is a cohesive, entrepreneurial team with a long history of shared success developing “win-win” partnerships with its portfolio companies and management teams. For more information, please visit the Kingswood website at www.kingswood-capital.com.

About CD&R

Founded in 1978, CD&R is a leading private investment firm with a strategy of generating strong investment returns by building more robust and sustainable businesses through the combination of skilled investment experience and deep operating capabilities. In partnership with the management teams of its portfolio companies, CD&R takes a long-term view of value creation and emphasizes positive stewardship and impact. The firm invests in businesses that span a broad range of industries, including industrial, healthcare, consumer, technology and financial services end markets. CD&R is privately owned by its partners and has offices in New York and London. For more information, please visit www.cdr.com and follow the firm’s activities through LinkedIn and @CDRBuilds on X/Twitter.

Source: Kingswood Capital Management, LP

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Union Pacific Insider Sold Shares Worth $1,875,000, According to a Recent SEC Filing
Union Pacific Insider Sold Shares Worth $1,875,000, According to a Recent SEC Filing
Jan 28, 2025
12:37 PM EST, 01/28/2025 (MT Newswires) -- Elizabeth F Whited, President, on January 24, 2025, sold 7,500 shares in Union Pacific ( UNP ) for $1,875,000. Following the Form 4 filing with the SEC, Whited has control over a total of 95,196 shares of the company, with 64,960 shares held directly and 30,237 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/100885/000010088525000031/xslF345X05/edgardoc.xml Price: 250.98,...
National Bank Previews Stingray Group Q3
National Bank Previews Stingray Group Q3
Jan 28, 2025
12:41 PM EST, 01/28/2025 (MT Newswires) -- National Bank is forecasting third-quarter revenue of $107.6 million and adjusted EPS of $0.34 for Stingray Group. Analyst Adam Shine expects Broadcasting & Commercial Music (B&CM) to deliver revenue growth of 11.7% to $73.3 million. B&CM is being driven by Retail Media platform, anchored by the U.S.-based InStore Advertising Network. Stingray Group reports...
Talen goes to court over FERC's Amazon co-located data center rejection
Talen goes to court over FERC's Amazon co-located data center rejection
Jan 28, 2025
NEW YORK, Jan 28 (Reuters) - Talen Energy ( TLN ) is asking a U.S. appeals court to weigh in on a decision by federal regulators last year to reject a power agreement for an Amazon ( AMZN ) data center connected directly to Talen's Pennsylvania nuclear plant, according to court filings this week. As Big Tech attempts to quickly...
Atai Life Sciences Reports Positive Topline Results From Alcohol Use Disorder Treatment Study
Atai Life Sciences Reports Positive Topline Results From Alcohol Use Disorder Treatment Study
Jan 28, 2025
12:42 PM EST, 01/28/2025 (MT Newswires) -- Atai Life Sciences ( ATAI ) said Tuesday the results of a phase 2a study of Beckley Psytech's BPL-003 in patients with moderate to severe alcohol use disorder were encouraging. The open-label study involved 12 patients, who were given a single dose of BPL-003, in combination with relapse prevention cognitive behavioral therapy, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved